Sorafenib Tosylate With or Without Everolimus in Treating Patients With Localized, Unresectable, or Metastatic Liver Cancer

NCT ID: NCT01005199

Last Updated: 2019-05-15

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 106 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2009-11-30
• Study Completion Date: 2016-03-31

Brief Summary

RATIONALE: Sorafenib tosylate and everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.

PURPOSE: This randomized phase II trial is studying giving sorafenib tosylate together with everolimus to see how well it works compared with sorafenib tosylate alone in treating patients with localized, unresectable, or metastatic liver cancer.

Detailed Description

OBJECTIVES:

• To determine if sorafenib tosylate with versus without everolimus can stop tumor progression in patients with localized, unresectable, or metastatic hepatocellular carcinoma.
• To evaluate changes in symptom-related and global quality of life (QL) and QL benefit over the course of trial treatment in these patients.
• To compare the primary endpoint (i.e., progression-free survival at week 12) to the QL benefit within 12 weeks from baseline.
• To evaluate how symptom-related and global QL indicators map on the single summary index derived from a standardized measure of health status for utility cost analysis.

OUTLINE: This is a multicenter study. Patients are stratified according to WHO performance status (0 vs 1), disease spread (extrahepatic spread vs non-extrahepatic spread), and center. Patients are randomized to 1 of 2 treatment arms.

• Arm A (standard treatment): Patients receive oral sorafenib tosylate twice daily for 4 weeks. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
• Arm B (investigational treatment): Patients receive oral sorafenib tosylate twice daily and oral everolimus once daily for 4 weeks. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.

Some patients may undergo CT scan or MRI at baseline and at 6 and 12 weeks during study to assess tumor response, tumor size, and tumor density.

Patients complete quality of life questionnaires at baseline and every 2 weeks for 12 weeks during study treatment.

After completion of study treatment, patients are followed every 2 months for 3 years.

Conditions

Liver Cancer

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Arm A: Sorafenib standard

• Arm A (standard treatment): Sorafenib 2 x 400 mg daily until progressive disease, unacceptable toxicity, or consent withdrawal. (46 patients).

Group Type: EXPERIMENTAL

sorafenib tosylate

Intervention Type: DRUG

Sorafenib 2 x 400 mg daily

Arm B: Sorafenib + everolimus

• Arm B (investigational treatment): Sorafenib 2 x 400 mg daily plus everolimus 1 x 5 mg daily until progressive disease, unacceptable toxicity, or consent withdrawal. (60 patients)

Group Type: EXPERIMENTAL

everolimus

Intervention Type: DRUG

Sorafenib 2 x 400 mg daily plus everolimus 1 x 5 mg daily

sorafenib tosylate

Intervention Type: DRUG

Sorafenib 2 x 400 mg daily

Interventions

everolimus

Sorafenib 2 x 400 mg daily plus everolimus 1 x 5 mg daily

Intervention Type: DRUG

sorafenib tosylate

Sorafenib 2 x 400 mg daily

Intervention Type: DRUG

Other Intervention Names

RAD001; BAY 43-9006

Eligibility Criteria

Inclusion Criteria

DISEASE CHARACTERISTICS:

• Histologically, cytologically, or radiologically confirmed hepatocellular carcinoma (HCC)

• Localized, unresectable, or metastatic disease
• Child-Pugh class A or mildly decompensated Child-Pugh class B liver dysfunction (Child-Pugh score ≤ 7)
• Stage B or C disease according to the Barcelona Clinic Liver Cancer (BCLC) staging classification
• Measurable disease

• At least 1 unidimensionally measurable site of disease (≥ 10 mm in case of a non-nodal lesion or with a short axis ≥ 15 mm in case of a lymph node) by spiral/multi-slice CT/MRI scan according to revised RECIST criteria
• No locally advanced disease AND a candidate for radical surgery
• No known fibrolamellar HCC or mixed cholangiocarcinoma/HCC
• No clinical symptoms or history of CNS metastases or leptomeningeal disease (no imaging required)

PATIENT CHARACTERISTICS:

• WHO performance status 0-1
• Hemoglobin ≥ 90 g/L
• Neutrophil count ≥ 1.5 x 10^9/L
• Platelet count ≥ 75 x 10^9/L
• Creatinine clearance ≥ 40 mL/min
• ALT ≤ 5 times upper limit of normal
• INR ≤ 2
• Urine dipstick for proteinuria ≤ 1+ OR protein spot urine < 0.6 g/L
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception during and for 12 months after completion of study therapy
• No prior malignancy within the past 5 years except adequately treated carcinoma in situ of the cervix or localized nonmelanoma skin cancer
• No history of hemorrhagic or thrombotic cerebrovascular event within the past 12 months
• No documented variceal hemorrhage within the past 3 months
• No requirement for anticoagulant therapy except for low-dose anticoagulants for maintenance of patency of central venous access or prevention of deep vein thrombosis
• No history or presence of clinically significant acute or unstable cardiovascular, cerebrovascular, renal, gastrointestinal, pulmonary, endocrine, central nervous system, or immunological disorders (except for the presence of hepatitis B or C virus or cirrhosis) within the past 6 months
• No encephalopathy
• No known HIV infection
• No active infection requiring IV antibiotics
• No arterial hypertension ≥ 150/100 mm Hg despite therapy
• No ongoing cardiac dysrhythmias of NCI CTCAE grade ≥ 2, atrial fibrillation of any grade, prolongation of QTc > 500 msec on screening electrocardiogram (ECG), or history of familial long QT syndrome
• No repeated paracentesis (more than 1 per month)
• No psychiatric disorder precluding understanding of information of trial-related topics, giving informed consent, or interfering with compliance for oral drug intake
• No concurrent grapefruit, grapefruit juice, or products containing bitter oranges
• Able to take oral medications
• Completed baseline quality of life questionnaire
• Must be compliant and geographically proximal for follow-up

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics
• No prior systemic anticancer treatment for this disease

• The following prior therapies are allowed provided previously treated lesions remain separate from those to be measured in the current trial and prior treatment is completed within the past 4 weeks

• Surgery
• Liver-directed therapy (e.g., transarterial embolization/chemoembolization [limited to 5 treatments], radiofrequency ablation, cryoablation, radiotherapy, or percutaneous ethanol injection)
• No prior organ transplantation
• No concurrent estrogen-containing supplementary therapy
• No concurrent full-dose anticoagulation with coumarin derivatives
• No concurrent elective major surgery
• No concurrent radiotherapy (concurrent analgesic radiotherapy of non-target lesions allowed)
• No concurrent or anticipated need for CYP3A4 inhibitors or inducers, unless the drugs are medically necessary and no substitutes are available, including any of the following:

• Ketoconazole
• Itraconazole
• Voriconazole
• Erythromycin
• Clarithromycin
• Diltiazem
• Verapamil
• Protease inhibitors
• No concurrent strong CYP3A4 inducers*, including any of the following:

• Carbamazepine
• Continuous dexamethasone (> 2 mg/day for > 7 days)
• Phenobarbital
• Phenytoin
• Rifampicin
• St. John's wort NOTE: *Concurrent antacids allowed provided they are administered > 1 hour before or > 1 hour after trial drug administration.
• No other concurrent experimental drugs or anticancer therapy or treatment in another clinical trial within the past 30 days
• No other concurrent investigational drugs
• No chronic systemic steroids or other immunosuppressive agents
• No concurrent angiotension converting enzyme inhibitors (ACE-I)

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Swiss Cancer Institute

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Dieter Koeberle, MD

Role: STUDY_CHAIR

Cantonal Hospital of St. Gallen

Jean-Francois Dufour, MD

Role: STUDY_CHAIR

Insel Gruppe AG, University Hospital Bern

Gyorgy Bodoky, MD, PhD

Role: STUDY_CHAIR

Szent Laszlo Korhaz

Michael Montemurro, MD

Role: STUDY_CHAIR

CHUV Lausanne

Locations

Medizinische Universität Wien

Vienna, , Austria

Szent Laszlo Korhaz

Budapest, , Hungary

Saint Claraspital AG

Basel, , Switzerland

Clinical Cancer Research Center at University Hospital Basel

Basel, , Switzerland

Istituto Oncologico della Svizzera Italiana - Ospedale Regionale Bellinzona e Valli

Bellinzona, , Switzerland

Inselspital Bern

Bern, , Switzerland

Kantonsspital Bruderholz

Bruderholz, , Switzerland

Hopital Cantonal Universitaire de Geneve

Geneva, , Switzerland

Centre Hospitalier Universitaire Vaudois

Lausanne, , Switzerland

Kantonsspital Liestal

Liestal, , Switzerland

Kantonsspital - St. Gallen

Sankt Gallen, , Switzerland

CHCVS - Hôpital de Sion

Sion, , Switzerland

Regionalspital

Thun, , Switzerland

City Hospital Triemli

Zurich, , Switzerland

UniversitaetsSpital Zuerich

Zurich, , Switzerland

Countries

Austria; Hungary; Switzerland

References

Koeberle D, Dufour JF, Demeter G, Li Q, Ribi K, Samaras P, Saletti P, Roth AD, Horber D, Buehlmann M, Wagner AD, Montemurro M, Lakatos G, Feilchenfeldt J, Peck-Radosavljevic M, Rauch D, Tschanz B, Bodoky G; Swiss Group for Clinical Cancer Research (SAKK). Sorafenib with or without everolimus in patients with advanced hepatocellular carcinoma (HCC): a randomized multicenter, multinational phase II trial (SAKK 77/08 and SASL 29). Ann Oncol. 2016 May;27(5):856-61. doi: 10.1093/annonc/mdw054. Epub 2016 Feb 15.

Reference Type: RESULT

PMID: 26884590 (View on PubMed)

Other Identifiers

SWS-SAKK-77/08

Identifier Type: OTHER

Identifier Source: secondary_id

SWS-SASL-29

Identifier Type: -

Identifier Source: secondary_id

2009-011884-35

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

EU-20983

Identifier Type: -

Identifier Source: secondary_id

CDR0000657702

Identifier Type: -

Identifier Source: secondary_id

SAKK 77/08 and SASL 29

Identifier Type: -

Identifier Source: org_study_id